Skip to main content

Table 3 Summary of DNA methylation biomarkers in melanoma

From: Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities

Methylated gene(s) Methylation association Hazard ratioa Reporting study
WIF1, TFPI2, RASSF1A and SOCS1 Advanced clinical stage [34]
17-gene (see text) Overall survival 2.41 (1.02–5.7) [120]
RASSF1A, RAR-beta2, MGMT Shorter overall survival 2.38 (1.1–4.8) [117]
KIT, DSP, HCK, IL18 Shorter overall survival [45]
HOXD9 Shorter overall survival 2.7 (1.1–6.5) [49]
LINE-1 Shorter overall survival 2.63 (1.2–5.6) [110]
MINT31 Longer overall survival 0.237 (not reported) [34]
TFPI2 Presence of metastases [172]
PTEN Shorter overall survival 3.76 (1.2–11.1) [14, 22]
MGMT Response to therapy - [113]
Longer progression-free survival 2.17 (1.3–3.5)
TSLC1 Progression-free survival - [112]
RASSF1A Resistance to therapy 0.21 (0.1–0.9) [117]
ESR1 Shorter overall survival 2.31 (1.4–5.5) [161]
Shorter progression free survival 2.64 (1.3–5.1)
p73 Sensitivity to therapy [173]
  1. aWhere applicable, with 95% confidence interval in parenthesis